Navigation Links
3-V Biosciences Presents Positive Data for Novel FASN Inhibitor at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Date:10/21/2013

MENLO PARK, Calif., Oct. 21, 2013 /PRNewswire/ -- 3-V Biosciences, Inc., a biopharmaceutical company developing therapeutics that modulate key host-cell pathways resulting in death of tumor cells or virally-infected cells, today presented positive data from preclinical studies of the company's novel fatty acid synthase (FASN) inhibitors. 

(Logo: http://photos.prnewswire.com/prnh/20121001/LA83573LOGO )

In a series of preclinical studies, 3-V's FASN inhibitors demonstrated potent activity against multiple tumor types, including breast, lung, pancreatic, ovarian and colon cancers.  FASN inhibition reduced cell proliferation and induced apoptosis (cell death) in a dose-dependent manner.  Of note, single-agent FASN inhibition both blocked tumor growth and resulted in significant tumor regression in patient-derived xenografts.  FASN inhibition was well tolerated at dose levels that achieved potent anti-cancer effect. 

"Our novel FASN inhibitor molecules demonstrate strong single-agent anti-cancer activity in vivo, and we are excited by the potential of these drugs to halt tumor growth and progression," said Merdad Parsey, M.D., Ph.D., Chief Executive Officer of 3-V Biosciences.  "FASN is a highly attractive target in oncology, but prior inhibitor programs have been challenged in aligning therapeutic efficacy with tolerability.  3-V's preclinical studies characterizing our FASN inhibitors point to a number of critical attributes, including potent tumor cell growth inhibition across a number of tumor types and a promising tolerability profile that should enable use in combination with standard of care.  We are ready to commence a Phase 1 clinical study for our lead candidate, TVB-2640, this year in patients with advanced solid tumors."

The company's lead clinical candidate,
'/>"/>

SOURCE 3-V Biosciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
2. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
3. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
4. Neurocrine Biosciences Reports First Quarter 2012 Results
5. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
6. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... 22, 2014 WHEN: Wednesday, October 29, 2014 ... available at: http://bit.ly/1yStiU9 SPEAKERS: Visionary ... Visionary Innovation Research Group Senior Research Analyst ... materials, nanobots and flexible electronics are among ... our lives in the coming decades. These ...
(Date:10/22/2014)... Conn. , Oct. 22, 2014  Recently published ... have bolstered the already substantial database of evidence. This ... adoption of Stretta therapy for sufferers of ... clinical evidence supporting Stretta therapy as a ... policies that make Stretta therapy available to nearly 50 ...
(Date:10/20/2014)... MOUNTAIN VIEW, California , 20 de octubre ... un líder en el campo de la pulmonología ... en su Estudio RENEW, casi 3 meses antes ... prueba fundamental de exención de dispositivo de investigación ... y Medicamentos) para el sistema de espiral de ...
Breaking Medicine Technology:Futuristic Technologies That Will Transform Our World Beyond 2030 2Futuristic Technologies That Will Transform Our World Beyond 2030 3Futuristic Technologies That Will Transform Our World Beyond 2030 4Recent Clinical Study Data Confirms Efficacy of Stretta Therapy - Spurs Additional Insurance Coverage and Financing Round 2PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3
... Oramed,Pharmaceuticals, Inc. (OTCBB: ORMP.OB) ( http://www.oramed.com ... today that its abstract, entitled "Open,Label Study ... (PD) of Five Oral Insulin Formulations in ... the upcoming 44th Annual,Meeting of the European ...
... MITI ), a biopharmaceutical company developing novel, ... autoimmune,diseases, will host a webcast and conference call ... Eastern Time (4:00 p.m. Central European,Time) to discuss ... Journal,SCIENCE on August 15, 2008., To access ...
Cached Medicine Technology:Oramed Pharmaceuticals Chosen to Present Oral Insulin Trial Results at EASD Conference (September 7-11, Rome) 2Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 2Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 3Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE 4
(Date:10/22/2014)... Angeles, California (PRWEB) October 22, 2014 Hay ... 2.0: Move Beyond Addiction and Upgrade Your Life (Paperback; $10.82) ... field of Yoga & Recovery. This book is meant ... thrive in a life of recovery. , Recovery 2.0 ... the 12 Steps; Recovery 2.0 is a guide for what ...
(Date:10/22/2014)... Plano, Texas (PRWEB) October 22, 2014 ... convenience of completing their continuing education at home ... now have access to 20 brand new, premium ... HomeCEUConnection.com’s robust catalog of over 2,000 hours ... to fully customize their educational experience. With such ...
(Date:10/22/2014)... of Prussia, PA (PRWEB) October 22, 2014 ... is recognized as an industry leader with over 25 ... award winning team leader in the areas related to ... addition, Mr. Carlson is an Editorial Advisory Board member ... Healthcare Council Educator. Blue Fin Group is a ...
(Date:10/22/2014)... -- Two sisters in high school have developed ways ... Medha Krishen use electronic stethoscopes, which electronically amplify body ... patterns or heartbeats. Ilina, a senior at Port ... a way to detect early lung damage in people ... Ilina recorded one breath cycle each from 16 smokers, ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
Breaking Medicine News(10 mins):Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 2Health News:Hay House Announces The Official Release of Recovery 2.0: Move Beyond Addiction and Upgrade Your Life 3Health News:Top Provider of Continuing Education at Home Releases 20 New Online Courses 2Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... named,Richard L. Wonsettler to the newly created position of ... Wonsettler, who has nearly 20 years of financial,management experience ... that Cohera Medical is preparing to enter the clinical ... "We are entering an important phase in the ...
... 30 /PRNewswire-FirstCall/ - SXC Health Solutions Corp.,("SXC" or ... a leading provider of,technology and pharmacy benefits management ... for its informedRx(R) pharmacy benefit management,("PBM") services with ... begin providing its services for more than 6,000 ...
... Response by End of Week -, LAVAL, ... DDS;,NASDAQ: DDSS) today announced that the Company has ... Administration (FDA) regarding its most recent,appeal of the ... once-daily,tramadol formulation through the Formal Dispute Resolution process., ...
... national investigation of the drug called Diditek. In April ... UDL Laboratories Digitek (digoxin tablets, USP, all strengths) for ... time many consumers or their families have received notification ... to talk to any consumer who took this drug ...
... new assistive technology developed by engineers at the ... severe disabilities lead more independent lives. , ... operate a computer, control a powered wheelchair and ... tongues. , "This device could revolutionize the field ...
... are twice as likely to develop rheumatoid arthritis in ... ahead of print in the Annals of the ... origin of disease theory, which argues that certain conditions ... during the pregnancy. , Diabetes, coronary heart disease, and ...
Cached Medicine News:Health News:Cohera Medical Names Richard L. Wonsettler as Company's First CFO 2Health News:The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services 2Health News:The University of Toledo selects SXC Health Solutions (informedRx) to provide pharmacy benefit management services 3Health News:Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product 2Health News:Labopharm Receives Response from FDA Regarding its Once-Daily Tramadol Product 3Health News:US Drug Watchdog Expands Its National Investigation Into The Drug Called Digitek, And Would Like To Talk To Possible Victims 2Health News:US Drug Watchdog Expands Its National Investigation Into The Drug Called Digitek, And Would Like To Talk To Possible Victims 3Health News:Tongue Drive system lets persons with disabilities operate powered wheelchairs, computers 2Health News:Tongue Drive system lets persons with disabilities operate powered wheelchairs, computers 3Health News:Tongue Drive system lets persons with disabilities operate powered wheelchairs, computers 4
MONOJECT Red/Yellow Mottled Stopper...
Inquire...
VACUETTE paediatric tubes have decreased sample volumes and are ideal for small childrens' veins and geriatric patients....
BD Vacutainer® Fluoride Tubes - Plastic...
Medicine Products: